Síndrome metabólico y antipsicóticos atípicos. Posibilidad de predicción y control

Second Generation Antipsychotics (SGAs) in Schizophrenic Patients and Bipolar Disorder: Correlation With Metabolic Syndrome (NCEP ATP III(a))

“…Despite the above, there are studies that do demonstrate the relationship between antipsychotics and the syndrome, in which adverse effects were detected by the use of second generation antipsychotics in patients with chronic schizophrenia, such as weight gain due to the use of olanzapine and from here on with the metabolic syndrome (Aguilar, Coronas, & Caixàs, 2012;Cortés Morales, 2011;De Hert et al, 2009;Estévez et al, 2013;Jaramillo et al, 2013;McEvoy et al, 2005;Muñoz & Gallardo, 2004;Newcomer, 2007aNewcomer, , 2007bPato et al, 2017;Vancampfort et al, 2015).…”

“…Second generation antipsychotics (SGAs), as a group can reduce the risk of producing extrapyramidal side effects and hyperprolactinemia when compared with first generation antipsychotics (FGAs) (Martínez, León, Torres, & Crossley, 2017;Cortés Morales, 2011;Pato, Rodríguez, & Valverde, 2017). However, there is scientific evidence suggesting that the interaction of these may increase the risk of significant weight, insulin resistance metabolic homeostasis, hyperglycemia, diabetes mellitus (DM) type 2 and dyslipidemia which could reduce life expectancy in patients who need these drugs as schizophrenic patients and with bipolar disorder (Cortés Morales, 2011).…”

Is obstructive sleep apnea the missing link between metabolic syndrome and second-generation antipsychotics: Preliminary study

“…[ 2 6 ] While previous literature suggested a link between the SGAs and metabolic syndrome;[ 4 9 ] contrarily, the recent literature has questioned this association. [ 1 3 5 ] Two 24 months long trials failed to report any change in physical and metabolic profile among patients taking SGAs. [ 1 5 ] Going along with the recent findings, in the present study too, we did not find any association between SGAs and metabolic syndrome [Tables 2 and 3 ].…”

“…[ 1 3 5 ] Two 24 months long trials failed to report any change in physical and metabolic profile among patients taking SGAs. [ 1 5 ] Going along with the recent findings, in the present study too, we did not find any association between SGAs and metabolic syndrome [Tables 2 and 3 ]. Moreover, there is a shift in understanding of the pathogenesis of metabolic syndrome in this group.…”

“…Metabolic syndrome has been found to be associated with schizophrenia and mood disorders across a number of studies, both in drug naïve as well as patients who have received medications but with conflicting results. [ 1 2 3 4 5 6 7 ] Available literature suggests higher prevalence of metabolic syndrome in drug-naïve participants with schizophrenia compared to control population with average prevalence of 10.8%. [ 3 ] However, this prevalence increases largely in participants taking second-generation antipsychotics (SGAs) and ranges between 11% and 69%.…”